JP2025510741A5 - - Google Patents

Info

Publication number
JP2025510741A5
JP2025510741A5 JP2024556229A JP2024556229A JP2025510741A5 JP 2025510741 A5 JP2025510741 A5 JP 2025510741A5 JP 2024556229 A JP2024556229 A JP 2024556229A JP 2024556229 A JP2024556229 A JP 2024556229A JP 2025510741 A5 JP2025510741 A5 JP 2025510741A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
cycloalkyl
independently
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/082518 external-priority patent/WO2023179542A1/en
Publication of JP2025510741A publication Critical patent/JP2025510741A/ja
Publication of JP2025510741A5 publication Critical patent/JP2025510741A5/ja
Pending legal-status Critical Current

Links

JP2024556229A 2022-03-21 2023-03-20 ヘテロ環式ｇｌｐ－１アゴニスト Pending JP2025510741A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/082067 2022-03-21
CN2022082067 2022-03-21
CNPCT/CN2022/085519 2022-04-07
CN2022085519 2022-04-07
CN2023080471 2023-03-09
CNPCT/CN2023/080471 2023-03-09
PCT/CN2023/082518 WO2023179542A1 (en) 2022-03-21 2023-03-20 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes

Publications (2)

Publication Number Publication Date
JP2025510741A JP2025510741A (ja) 2025-04-15
JP2025510741A5 true JP2025510741A5 (enExample) 2026-04-08

Family

ID=86054039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556229A Pending JP2025510741A (ja) 2022-03-21 2023-03-20 ヘテロ環式ｇｌｐ－１アゴニスト

Country Status (5)

Country Link
US (1) US20250206757A1 (enExample)
EP (1) EP4496797A1 (enExample)
JP (1) JP2025510741A (enExample)
CN (1) CN119212993A (enExample)
WO (1) WO2023179542A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
EP4317145A4 (en) * 2021-03-24 2025-03-12 Shionogi & Co., Ltd Pharmaceutical composition containing glp-1 receptor agonist having fused ring
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
CN119907794A (zh) * 2022-09-22 2025-04-29 盐野义制药株式会社 具有glp-1受体激动剂作用的稠环化合物
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2026039329A1 (en) * 2024-08-13 2026-02-19 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039528A (en) 1989-12-11 1991-08-13 Olney John W EAA antagonists as anti-emetic drugs
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US6628343B1 (en) 1997-05-23 2003-09-30 Sony Corporation Television signal reception circuit, automatic phase shift control circuit and equal amplitude addition circuit
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF
AU2001288690A1 (en) 2000-09-05 2002-03-22 Odyssey Pharmaceuticals Llc Two-component anti-emetic composition comprising dexamethasone and metoclopramide
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
US6673792B1 (en) 2002-07-11 2004-01-06 Upchuck, Llc Broad-spectrum anti-emetic compositions and associated methods
PT2208727E (pt) * 2002-09-19 2012-10-11 Lilly Co Eli Éteres diarílicos como antagonista do receptor opióide
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ 新規なｇｌｐ−１化合物
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US7402596B2 (en) * 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
JP2008536881A (ja) 2005-04-21 2008-09-11 ガストロテック・ファルマ・アクティーゼルスカブ Ｇｌｐ−１分子と制吐剤との医薬製剤
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
JP4094660B1 (ja) 2005-08-10 2008-06-04 武田薬品工業株式会社 糖尿病治療剤
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
ES2596532T3 (es) * 2006-03-16 2017-01-10 Second Genome, Inc. Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
US20080051387A1 (en) * 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
EP2072050A1 (en) 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Compounds with anti-emetic effect
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
US20120021979A1 (en) 2010-06-24 2012-01-26 Vanderbilt University GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
US20120101089A1 (en) 2010-10-26 2012-04-26 Ashwani Agarwal Anti-Emetic Substance
JP6126097B2 (ja) 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
US10071088B2 (en) 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
JP6573604B2 (ja) 2013-06-11 2019-09-11 セルジーン インターナショナル ツー エスエーアールエル 新規なｇｌｐ−１レセプターモジュレーター
CN107074820B (zh) 2014-07-25 2021-05-18 赛尔基因第二国际有限公司 Glp-1受体调节剂
GB201506116D0 (en) 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
EP3723743A4 (en) 2017-12-15 2021-09-08 Montero Gida Sanayi Ve Ticaret Anonim Sirketi DRUG COMBINATION INCLUDING DAPOXETINE, PHOSPHODIESTERASE TYPE 5 INHIBITOR AND ANTIEMETIC AGENT
KR102983496B1 (ko) * 2019-03-14 2026-06-29 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
US20230322771A1 (en) * 2020-09-07 2023-10-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4317145A4 (en) * 2021-03-24 2025-03-12 Shionogi & Co., Ltd Pharmaceutical composition containing glp-1 receptor agonist having fused ring
CN115594669B (zh) * 2021-07-09 2024-11-05 深圳信立泰药业股份有限公司 一种并环类衍生物及其制备方法和医药用途

Similar Documents

Publication Publication Date Title
JP2025504508A5 (enExample)
KR102344561B1 (ko) Glp-1 수용체 작용제 및 이의 용도
US12378230B2 (en) GLP-1 receptor agonists and uses thereof
JP7053900B2 (ja) Ｇｌｐ－１受容体アゴニストおよびその使用
WO2022031994A1 (en) Glp-1r agonists and uses thereof
US20240067630A1 (en) Aryl ether-substituted heterocyclic compounds as glp1r agonists
US20240294525A1 (en) Compounds as glp-1 receptor agonists and uses thereof
JP5847533B2 (ja) 新規甲状腺ホルモンβ受容体作動薬
US20080058339A1 (en) New compounds
WO2025057134A2 (en) Glp-1r agonist and therapeutic method thereof
KR20210059584A (ko) Glp-1 수용체 작용제 및 이의 용도
JP2010523692A (ja) 新規合成物
JP2025513071A5 (enExample)
TW202527937A (zh) 多環化合物及其用途
CN119907794A (zh) 具有glp-1受体激动剂作用的稠环化合物
JP2020023570A (ja) ２，６−ジ置換ピリジン誘導体
JP2013047188A (ja) Ｇｐｒ１１９作動薬
TW403745B (en) Novel substituted -amidinobenzene derivative and pharmaceutical compositions thereof
KR101984281B1 (ko) Gpr119 작용 활성을 갖는 신규 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
RU2021131781A (ru) Агонисты glp-1r и их применения
RU2021117868A (ru) Агонисты glpglp-1r и их применения
EA047423B1 (ru) Агонист рецептора glp-1 и его применение
JP2020050656A (ja) ２，６−ジ置換ピリジン誘導体からなる医薬